Judge Denies Defendants’ Motions for Partial Summary Judgement in Xarelto Case

There are currently thousands of Xarelto cases which have been consolidated in multidistrict litigation in the Eastern District of Louisiana. The Plaintiffs allege that they or their family members suffered severe bleeding and other injuries due to Xarelto’s allegedly defective design and inadequate warning label, among other things.

On April 13, 2017, the Louisiana federal judge overseeing this litigation denied the Defendants’ two motions for partial summary judgment. The Defendants had argued that federal law preempted some of the Plaintiffs’ claims because federal regulations prevented the manufacturer from updating labels or altering the dosage of the drug. U.S. District Judge Eldon Fallon disagreed, and found that the Defendants had not convincingly shown that federal regulations prevented the manufacturer of Xarelto from updating labels or creating more tailored dosing guidelines for Xarelto.

The first bellwether trial in the Xarelto litigation is set to start on April 24, 2017 in the U.S. District Court for the Eastern District of Louisiana. Wexler Wallace LLP is actively involved in Xarelto litigation and is reviewing claims involving people who took Xarelto and experienced severe, uncontrolled bleeding, stroke, or death. If you have suffered from any of these issues, you may have a Xarelto claim. Please contact Wexler Wallace LLP.